Articles > Securities Lawsuit Alert: Sana Biotechnology, Inc. (SANA)
- Multiple law firms announce class action lawsuits against Sana Biotechnology, Inc.
- Investors who suffered losses during a specific period urged to join the lawsuits
- Deadline for potential recovery under federal securities laws is May 20, 2025
- Lawsuits filed due to alleged violations of federal securities laws
- Investors can contact Levi & Korsinsky, Bronstein Gewirtz & Grossman, Rosen Law Firm, or Pomerantz Law Firm for more information
Several prominent law firms have announced class action lawsuits against Sana Biotechnology, Inc., urging investors who suffered losses during a specific period to join the legal actions before the impending deadline of May 20, 2025. The lawsuits have been filed based on allegations of violations of federal securities laws by Sana and certain company officers.
Investors who incurred losses on their Sana Biotechnology, Inc. (NASDAQ: SANA) investments between March 17, 2023, and November 4, 2024, known as the "Class Period," have the opportunity to potentially recover their losses through participation in these class action lawsuits. The legal actions aim to seek damages for all individuals and entities, except the defendants, who purchased or acquired Sana securities during the specified Class Period.
Multiple law firms, including Levi & Korsinsky, Bronstein Gewirtz & Grossman, Rosen Law Firm, and Pomerantz Law Firm, have initiated these class action lawsuits, addressing alleged violations of the federal securities laws by Sana Biotechnology, Inc. and some of its top officials. Investors are encouraged to reach out to these legal entities for further details on how to participate in the lawsuits and seek potential recovery under the federal securities laws.
The legal allegations against Sana Biotechnology, Inc. stem from actions taken by the company and certain officers between March 17, 2023, and November 4, 2024, which are claimed to have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5. To address these claims and pursue remedies, the class action lawsuits have been filed in the United States District Court for the Western District of Washington, docketed under 25-cv-00512.
With the deadline for the lead plaintiff submission set for May 20, 2025, investors who lost money on their Sana Biotechnology, Inc. investments are advised to act promptly and explore their options for participating in the class action lawsuits initiated by various law firms. By contacting Levi & Korsinsky, Bronstein Gewirtz & Grossman, Rosen Law Firm, or Pomerantz Law Firm, investors can obtain more information on how to potentially recover their losses under the federal securities laws.
For more information:
Up/Down Rally Price Distribution Analyst Recommendations Earning Price Impact Analysis Seasonality
Securities Lawsuit Alert: Sana Biotechnology, Inc. (SANA)
By KlickAnalytics Data Insights | May 20, 2025 08:02PM ET
Key Points
- Multiple law firms announce class action lawsuits against Sana Biotechnology, Inc.
- Investors who suffered losses during a specific period urged to join the lawsuits
- Deadline for potential recovery under federal securities laws is May 20, 2025
- Lawsuits filed due to alleged violations of federal securities laws
- Investors can contact Levi & Korsinsky, Bronstein Gewirtz & Grossman, Rosen Law Firm, or Pomerantz Law Firm for more information
Several prominent law firms have announced class action lawsuits against Sana Biotechnology, Inc., urging investors who suffered losses during a specific period to join the legal actions before the impending deadline of May 20, 2025. The lawsuits have been filed based on allegations of violations of federal securities laws by Sana and certain company officers.
Investors who incurred losses on their Sana Biotechnology, Inc. (NASDAQ: SANA) investments between March 17, 2023, and November 4, 2024, known as the "Class Period," have the opportunity to potentially recover their losses through participation in these class action lawsuits. The legal actions aim to seek damages for all individuals and entities, except the defendants, who purchased or acquired Sana securities during the specified Class Period.
Multiple law firms, including Levi & Korsinsky, Bronstein Gewirtz & Grossman, Rosen Law Firm, and Pomerantz Law Firm, have initiated these class action lawsuits, addressing alleged violations of the federal securities laws by Sana Biotechnology, Inc. and some of its top officials. Investors are encouraged to reach out to these legal entities for further details on how to participate in the lawsuits and seek potential recovery under the federal securities laws.
The legal allegations against Sana Biotechnology, Inc. stem from actions taken by the company and certain officers between March 17, 2023, and November 4, 2024, which are claimed to have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5. To address these claims and pursue remedies, the class action lawsuits have been filed in the United States District Court for the Western District of Washington, docketed under 25-cv-00512.
With the deadline for the lead plaintiff submission set for May 20, 2025, investors who lost money on their Sana Biotechnology, Inc. investments are advised to act promptly and explore their options for participating in the class action lawsuits initiated by various law firms. By contacting Levi & Korsinsky, Bronstein Gewirtz & Grossman, Rosen Law Firm, or Pomerantz Law Firm, investors can obtain more information on how to potentially recover their losses under the federal securities laws.
For more information:
Disclaimer: the above is a summary showing certain market information. KlickAnalytics is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from various resources and more. Communications displaying market prices, data and other information available in this post are meant for purely for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.